SCHEMBL20456547

SCHEMBL20456547

C=CC(=O)Nc1ccc(Oc2ccc(OC)cc2)cc1

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 7/20 0.90
SMN1; SMN2 Q16637 4/20 0.58
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
MTNR1A P48039 1/20 0.56
MTNR1B P49286 1/20 0.56
LMNA P02545 2/20 0.54
MAP2K7 O14733 1/20 0.54
F13A1 P00488 1/20 0.54
TGM1 P22735 1/20 0.54
TGM3 Q08188 1/20 0.54
MAPT P10636 2/20 0.54
ALDH1A1 P00352 1/20 0.54
POLB P06746 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
MMP1 P03956 2/20 0.54
MMP2 P08253 2/20 0.54
MMP9 P14780 2/20 0.54
EGFR P00533 1/20 0.54
TP53 P04637 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL782552 0.95 TGM2 (1.00) TGM2SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL14341775 0.91 TGM2 (0.86) TGM2SMN1; SMN2MTNR1AMTNR1BLMNA
SCHEMBL8467427 0.90 TGM2 (0.90) TGM2SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL8151744 0.88 MTNR1B (0.74) TGM2SMN1; SMN2MTNR1AMTNR1BALDH1A1
SCHEMBL9017578 0.85 TGM2 (1.00) TGM2SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL20456243 0.83 TGM2 (0.73) TGM2SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL20554088 0.83 TGM2 (0.62) TGM2MTNR1AMTNR1BMAP2K7EGFR
SCHEMBL20469621 0.83 TGM2 (0.68) TGM2SMN1; SMN2RAB9ALMNAMAP2K7
SCHEMBL20456556 0.83 TGM2 (0.68) TGM2SMN1; SMN2LMNAMAP2K7F13A1
SCHEMBL18559537 0.82 TGM2 (0.71) TGM2SMN1; SMN2NPC1RAB9AMTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062696-A1 COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-02-27 US disclosed
US-20200062696-A1 COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-02-27 US disclosed
CN-110461322-A For inhibiting the composition and method of plasma membrane protein 4 UNIV CALIFORNIA 2019-11-15 CN disclosed
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY FRONTIER MEDICINES CORPORATION 2019-09-26 US disclosed
WO-2018144870-A1 COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-08-09 WO disclosed
WO-2018144870-A1 COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062696-A1 COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 RTN4, RTN3, RCN1 TGM2 2492/4885SMN1; SMN2 2138/4885NPC1 2442/4885
US-20190290778-A1 METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY ATG7, BECN1, SQSTM1 TGM2 2225/4885SMN1; SMN2 3721/4885NPC1 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.